Pharmobedient Company Profile

What is the competitive landscape for PHARMOBEDIENT

PHARMOBEDIENT has three hundred and twenty-one approved drugs.

There is one US patent protecting PHARMOBEDIENT drugs. There is one tentative approval on PHARMOBEDIENT drugs.

There are twenty-one patent family members on PHARMOBEDIENT drugs in sixteen countries and six hundred and eighty-one supplementary protection certificates in nineteen countries.

Summary for Pharmobedient

International Patents:	21
US Patents:	1
Tradenames:	248
Ingredients:	236
NDAs:	321

Drugs and US Patents for Pharmobedient

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	LIOTHYRONINE SODIUM	liothyronine sodium	TABLET;ORAL	090326-002	Jul 14, 2009		DISCN	No	No
Pharmobedient	ROPINIROLE HYDROCHLORIDE	ropinirole hydrochloride	TABLET;ORAL	078881-006	May 5, 2008		DISCN	No	No
Pharmobedient	CHLORTHALIDONE	chlorthalidone	TABLET;ORAL	212878-001	Feb 24, 2022	AB	RX	No	No
Pharmobedient	METFORMIN HYDROCHLORIDE	metformin hydrochloride	TABLET;ORAL	075976-003	Jan 24, 2002		DISCN	No	No
Pharmobedient	DIDANOSINE	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	090788-001	Apr 8, 2010		DISCN	No	No
Pharmobedient	FLUVASTATIN SODIUM	fluvastatin sodium	TABLET, EXTENDED RELEASE;ORAL	202458-001	Sep 11, 2015		DISCN	No	No
Pharmobedient	LIDOCAINE	lidocaine	PATCH;TOPICAL	202346-001	Aug 7, 2015	AB	RX	No	No

Expired US Patents for Pharmobedient

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	DEMADEX	torsemide	TABLET;ORAL	020136-003	Aug 23, 1993	RE30633
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007	8,962,000
Pharmobedient	ZOVIRAX	acyclovir	TABLET;ORAL	020089-001	Apr 30, 1991	4,199,574
Pharmobedient	DEMADEX	torsemide	TABLET;ORAL	020136-002	Aug 23, 1993	RE34672
Pharmobedient	DEMADEX	torsemide	TABLET;ORAL	020136-001	Aug 23, 1993	RE34672
Pharmobedient	DEMADEX	torsemide	TABLET;ORAL	020136-003	Aug 23, 1993	RE34672
Pharmobedient	DUONEB	albuterol sulfate; ipratropium bromide	SOLUTION;INHALATION	020950-001	Mar 21, 2001	6,632,842

Paragraph IV (Patent) Challenges for PHARMOBEDIENT drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Topical Foam	0.05%		2005-06-27
	Foam	0.12%		2007-08-10
	Inhalation Solution	0.021% and 0.042%		2005-10-19

International Patents for Pharmobedient Drugs

Country	Patent Number	Estimated Expiration
Canada	2578594
Taiwan	200624124
Canada	2756674
South Korea	20070069155
Taiwan	I397427
Japan	2008511550
South Africa	200702702

Supplementary Protection Certificates for Pharmobedient Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2487166	2016/061	Ireland		PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061 20151119
1744764	18C1047	France		PRODUCT NAME: DAUNORUBICINE + CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
1539166	2013/055	Ireland		PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
0720599	300689	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912
0136011	99C0003	Belgium		PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
0273277	96C0039	Belgium		PRODUCT NAME: STAVUDINE; REGISTRATION NO/DATE: EU/1/96/009/001 19960508
1853250	C300673	Netherlands		PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pharm Assoc
• Pharm Res Assoc
• Pharm Spec
• Pharm Ventures
• Pharma Serve Ny
• Pharmaand
• Pharmacare

PHARMOBEDIENT Competitive Landscape Analysis: Market Position, IP Strength, and Strategic Moves

Last updated: July 10, 2026

Executive summary: PHARMOBEDIENT is not identifiable as a specific FDA-approved drug product, biologic, or active ingredient from the information provided. Without a determinable drug identity (active ingredient, brand name, sponsor/MAH, dosage form, and FDA application), no accurate Orange Book status, patent estate, exclusivity windows, Paragraph IV risk, or litigation can be mapped to support a competitive landscape assessment.

What is PHARMOBEDIENT in the US market, and who manufactures it?

Answer: Not determined from the provided input.

What active ingredient does PHARMOBEDIENT contain?

Not determined.

Is PHARMOBEDIENT an NDA, ANDA, BLA, or OTC product?

Not determined.

What dosage forms and strengths exist?

Not determined.

What is the Orange Book status of PHARMOBEDIENT?

Answer: Not determined.

Are there FDA-listed patents for PHARMOBEDIENT?

Not determined.

Which patent types appear (drug substance, drug product, method of use)?

Not determined.

What are the listed expiration dates and exclusivity end dates?

Not determined.

What patents protect PHARMOBEDIENT, and how strong is the patent estate?

Answer: Not determined.

How many patents cover PHARMOBEDIENT across composition, formulation, and use?

Not determined.

Who are the assignees of the key patents?

Not determined.

What jurisdiction coverage exists (US only vs. global families)?

Not determined.

When does PHARMOBEDIENT lose exclusivity or patent protection?

Answer: Not determined.

What are the expected earliest US launch dates for generics?

Not determined.

What exclusivity periods apply (NCE, 5-year, 3-year, pediatric, orphan)?

Not determined.

What is the timing risk for at-risk launches?

Not determined.

What generic entry risks exist for PHARMOBEDIENT, including Paragraph IV?

Answer: Not determined.

Have any Paragraph IV challenges been filed?

Not determined.

Which generic companies are potential challengers?

Not determined.

What settlement or consent judgments affect entry timing?

Not determined.

What formulations are protected by PHARMOBEDIENT patents?

Answer: Not determined.

Are there protected technologies (extended-release, tamper-resistant, particulate, co-crystal)?

Not determined.

Are manufacturing processes patented (drying, granulation, sterilization, aseptic fill-finish)?

Not determined.

What method-of-use patents protect PHARMOBEDIENT?

Answer: Not determined.

Are there line-extension indications (new dosing, patient subsets, combination regimens)?

Not determined.

What claim scopes are likely to be infringed by labeled use?

Not determined.

Which companies are challenging PHARMOBEDIENT, and what does litigation show?

Answer: Not determined.

What patent litigation affects PHARMOBEDIENT?

Not determined.

What are the key court dates and outcomes?

Not determined.

What patents were asserted, and against which generic applicants?

Not determined.

How does PHARMOBEDIENT compare with competing brands and generics?

Answer: Not determined.

What are the therapeutic alternatives and substitution patterns?

Not determined.

How do pricing and access differ among competitors?

Not determined.

Are there competitive differentiation levers (onset, safety, adherence, device delivery)?

Not determined.

What FDA regulatory pathway does PHARMOBEDIENT use, and how does it affect competitive entry?

Answer: Not determined.

Is it approved via 505(b)(1), 505(b)(2), or 505(j)?

Not determined.

Is there REMS, risk management, or restricted distribution?

Not determined.

Are there biosimilar-like risks (if PHARMOBEDIENT is a biologic)?

Not determined.

Commercial strategy: where is PHARMOBEDIENT exposed to revenue erosion?

Answer: Not determined.

What is the maturity of the market (new launch vs. entrenched)?

Not determined.

What are the most likely first-wave generic or switch drivers?

Not determined.

What payer pressures exist (PBM position, formulary status, prior auth)?

Not determined.

Key Takeaways

• PHARMOBEDIENT cannot be connected to a specific US-regulated product, active ingredient, or FDA application based on the provided input.
• No defensible analysis of Orange Book listings, exclusivity timelines, patent scope, Paragraph IV risk, litigation, or competitive substitution can be produced without a determinable drug identity.

FAQs

1. How do I find the correct Orange Book record for a brand when the manufacturer is unclear?
2. What is the typical patent coverage map for a US small-molecule brand (drug substance, drug product, method-of-use)?
3. How does pediatric exclusivity interact with listed Orange Book patents for launch timing?
4. What claim elements most often drive non-infringement or design-around arguments in Paragraph IV cases?
5. What data points best predict generic erosion risk for an established brand (patent count, expirations, exclusivity end dates, litigation posture)?

References

1. Not provided.